depicted below, and will be used throughout this manuscript to provide a framework for understanding the data (or lack thereof) supporting any recommendations made (Table 1) .
| MONOCLONAL G AMMOPATHY OF UNDE TERMINED S IG NIFIC AN CE

| Background
Monoclonal gammopathy of undetermined significance (MGUS) is the most frequently encountered plasma cell dyscrasia in clinical practice. 2 MGUS is defined as the presence of a serum monoclonal protein <3.0 g/dL, <10% clonal plasma cells in the bone marrow, and the absence of end-organ damage related to the disorder. The diagnostic criteria for plasma cell disorders is depicted in Table 2 . 2 In a large study, the prevalence of MGUS was estimated at 3.2%, in a predominantly white population. 3 The most important risk of MGUS is progression to MM. A long-term study of MGUS patients, showed a cumulative probability of progression to symptomatic multiple myeloma of 12% at 10 years, 25% at 20 years, and 30% at 25 years. 4 
| Management of MGUS
The International Myeloma Working Group (IMWG) has published guidelines for the assessment of risk of progression in MGUS in the general population (Table 3) , by analyzing the combination of serum monoclonal protein level, serum free light chain levels, and immunoglobulin isotype. 5 The risk classification system forms a basis for recommendations regarding management and prognosis of MGUS in the general population, which are extrapolated to the organ transplantation patient population (Tables 3 and 4) . Following the diagnosis of an MGUS, and after careful evaluation for other types of plasma cell disorders, patients should be followed as per the European Myeloma Network guidelines 6 (Table 4 ).
| MGUS in solid organ transplant
In large study of 1016 kidney transplant patients, only 16 of 1016 (1.6%) patients had an MGUS at any time; 5 of 16 were diagnosed pre-kidney transplant, and 11 of 16 were diagnosed post-kidney transplant. 7 In a retrospective analysis of the Healthcare Cost and Utilization Project in California, only 72 of 22 062 organ-transplant patients had a known MGUS prior to OT (0.3%). 8 Another large retrospective analysis of 1593 organ-transplant patients revealed a monoclonal spike in 2.8% of patients. 9 Some degree of selection bias may be present in these results-as many transplant centers will not list or transplant patients with MGUS. This may explain the lower incidence described in these studies, as compared with the incidence in the general population described previously.
Given the inherent risks of progression to MM and the long-term immunosuppression that organ-transplant patients need-there is concern for increased risk for development of MM or other plasma cell disorders in patients with MGUS who undergo organ transplant.
Immunosuppression following organ transplant can result in higher incidence of developing malignancy-approximately three to five times the general population, with non-melanoma skin cancer and non-Hodgkin lymphoma being the most common secondary malignancies. 10 To answer this clinical concern, there are many retrospective series examining the impact of MGUS in the pre-organ transplant setting, and also in post-organ transplant patients. The data from each of these settings are summarized as follows.
| MGUS and all organ transplantation data
A large, retrospective analysis of the California Healthcare Cost and 
| MGUS and kidney transplantation
Several small retrospective studies have examined the impact of MGUS (both in the pre-and post-organ transplant setting) on out- 
| MGUS in heart transplantation
In 2001, one study was published examining outcomes of MGUS patients undergoing heart transplant. This publication looked at risk factors for MGUS in a heart transplant population of 308 patients from a single center. 14 In this population, MGUS was common (76 patients, or 25%), but importantly, no patients with MGUS developed MM. Beyond the liver-transplant population, there are few data focusing on specific less common transplants such as lung or pancreas.
| MGUS and other organ-transplant populations
Further research is needed in these populations to define the impact of an MGUS diagnosis on long-term outcomes and risk of developing subsequent malignancy.
| MGUS and living donors
During the last decade, living kidney donor transplantation has increased in numbers, and given the long wait lists for deceased donor kidney transplants, may be the only practical option for some patients. 17, 18 The Amsterdam Criteria for living kidney donors, published in 2005, specifically advises against the use of donors with a monoclonal gammopathy. 19 Since then, there have been concerning reports in the literature regarding the impact of MGUS in a living donor kidney transplant. In a report of 2 cases wherein the donor had an MGUS, neither of the 2 recipients developed multiple myeloma nor any complications. 20 However, another report of 2 organ donors, and 7 organ recipients, described transmission of PTLD to all 7 recipients (2 cases of lymphoplasmacytic lymphoma, 2 MGUS, 3 cases of MM). 21 The origin of malignancy (ie, donor derived) was confirmed using microsatellite analysis. There have been 2 other case reports of myeloma of donor origin arising after kidney transplant. 22, 23 At this time, further study is needed with large registrybased analyses to determine the cause and effect relationship of donor MGUS and PTLD in recipients.
| MGUS recommendations
1. Based on the current data, we do not recommend routinely testing organ transplant recipients for MGUS, either in the pre-and posttransplant settings (Level 4).
2.
Based on limited, nonrandomized retrospective evidence, we do not think that a diagnosis of MGUS in a recipient should preclude organ transplantation (Level 3).
TA B L E 3 Risk stratification for monoclonal gammopathy of undetermined significance in the general population 
If a potential organ transplant recipient is known to have
MGUS, then further testing (Table 2 ) is needed to evaluate for an active plasma cell disease, based on current guidelines (Tables 3 and 4 ).
| MULTIPLE MYELOMA
| Background
Multiple myeloma (MM) is the most common plasma cell neoplasm, classically characterized by the "CRAB" criteria (hypercalcemia, renal failure, anemia, bone lesions). Currently MM is considered an incurable cancer, but survival for multiple myeloma has been improving with better therapies. From 1975 to 1977, the 5-year survival rate was only 25%, whereas more recently, from 2005 to 2011, the 5-year survival rate has improved to 49%. 24 It is important to note that the diagnosis of MM no longer imparts a poor and rapidly lethal prognosis for patients. The disease is now highly treatable in the majority of patients. In fact, the survival of MM patients is now similar to that of otherwise similar patients without MM. 25 The diagnosis of MM is made with the presence of ≥10% clonal bone marrow plasma cells, or presence of a biopsy-proven bony or extramedullary plasmacytoma, with one or more myelomadefining events (Table 1) . 26 Myeloma-defining events include both evidence of end-organ disease, and biomarkers of malignancy (Table 2) .
Therapy for newly diagnosed multiple myeloma in 2017 consists of two or three drug combinations of proteasome inhibitors, immunomodulatory drugs, and steroids. 27 Approved immunomodulatory drugs include lenalidomide, thalidomide, and pomalidomide.
The mechanism of action of these drugs involves binding to cereblon, which results in activation of cereblon E3 ligase activity. [28] [29] [30] Proteasome inhibitors include bortezomib, ixazomib, and carfilzomib. Bortezomib reversibly inhibits the 20S proteasome, resulting in stress on the unfolded protein response pathway, and inhibition of NF-kappa B, leading to apoptosis.
31
Autologous stem cell transplantation (ASCT) is a standard component of initial therapy for eligible patients, depending on age, overall health, and organ function. Although ASCT is not a curative treatment, it is a highly effective therapy for many patients that can provide meaningful, long-term remissions from myeloma. For patients who are eligible, upfront treatment with the triplet regimen VRD (bortezomib, lenalidomide, and dexamethasone), followed by consolidation with ASCT followed by long-term maintenance therapy is the preferred approach. 27 Maintenance therapy-defined as a low dose of an effective therapy after initial treatment-has been studied after autologous transplantation with lenalidomide and bortezomib, and both drugs are effective at prolonging remissions.
32,33
For those who are transplant ineligible, upfront treatment with two or three drug combinations, followed by maintenance therapy is the standard approach. Proteasome inhibitors such as bortezomib have a risk of neuropathy, and immune suppression leading to reactivation of shingles. 35, 36 A thorough discussion of post-ASCT complications is beyond the scope of this paper, but immunocompromised state lasts well beyond engraftment, and infectious complications may occur up to a year post-ASCT.
| Kidney transplantation in multiple myeloma
Acute kidney injury (AKI) is a common end-organ complication of multiple myeloma. Up to 50% of patients with newly diagnosed MM will present with AKI secondary to multiple myeloma. 37 Although formerly associated with a poor prognosis in newly diagnosed MM, introduction of newer drugs has led to an improvement in outcomes for patients with AKI secondary to MM. 38 Despite improved out- with respect to initiating anti-myeloma therapy is increased risk of infections while on immunosuppression and combination novel drug therapy for MM. There are few data to suggest that decreasing immunosuppression can lead an MM PTLD to resolve.
| MONOCLONAL G AMMOPATHY OF RENAL S IG NIFIC AN CE
| Background
Monoclonal gammopathy of renal significance (MGRS) is a term defining monoclonal gammopathies that result in kidney disease.
The most common plasma cell dyscrasias a clinician will encounter that fall under the MGRS category include light chain deposition disease (LCDD), cryoglobulinemia (Type 1 and 2), and monoclonal gammopathy-associated C3 glomerulopathy. 45 Most critical for the clinician assuming care of MGRS patients is having tools to prevent further renal impairment and understanding the role of kidney transplant in this disease group. Herein, we will review some of the more common MGRS diseases, and the data supporting kidney transplant for each.
| Light chain deposition disease
| Background
Light chain deposition disease results from deposition of immunoglobulin light-chains along the glomerular and tubular basement membranes of the kidneys. 46 Proteinuria is a common presenting sign, with subsequent development of progressive decline in renal function and irreversible damage, often resulting in need for longterm renal replacement therapy. 46 The underlying cause for LCDD is excessive production of abnormal immunoglobulins by a clonal plasma cell dyscrasia. Treatment thus targets the underlying clonal plasma cell disease with systemic chemotherapy and novel agents.
Initial studies examining ASCT in LCDD have documented successful long-term remissions (ie, long periods of time, on the order of years, without evidence for disease recurrence). An early study in 2004 described outcomes in 11 patients with LCDD undergoing ASCT. 47 No reports of ASCT related mortality were described, and 8 of 11 patients had disease response, with histologic regression documented in cardiac, liver, and skin biopsies. Another publication in 2008 showed good tolerability of ASCT and long-lasting responses. 48 Of 6 patients with LCDD who underwent ASCT, 5
survived, all of whom achieved a remission of their disease. The median reduction in proteinuria was 92%, and median improvement in GFR was 95%.
| Kidney transplantation in LCDD
In patients with LCDD, with effective treatment of the primary hematologic disorder with ASCT, one could consider solid organ transplant for patients with dialysis-dependent renal failure.
However, this idea has had little enthusiasm, given concerns for recurrence of the plasma cell disorder and organ damage from immunoglobulin deposition. The pertinent literature will be reviewed to follow.
The earliest publication, in 2004, was a retrospective review of 7 patients with LCDD who underwent kidney transplant. 49 In this study, renal allograft survival was noted to be significantly reduced, with a median of 33.8 months to recurrence of renal disease. A later publication in which 9 patients underwent transplant for LCDD described 3 of 9 patients who had renal progression, and 6 of 9 who had progression of the underlying plasma cell disorder, but were initiated on subsequent plasma cell directed therapy and had a response to that, without any worsening of renal disease. 46 Another group at a large referral center reported on a large cohort of patients with LCDD who were followed there. 50 Of 53 patients with LCDD, 7 underwent kidney transplant, and for those patients with long-term remission of the plasma cell disorder, there was no evidence of recurrence of LCDD up to 9.7 years later.
Accordingly, there was noted to be a strong relationship between response of the underlying disease and renal outcomes with respect to kidney transplant.
| Kidney transplantation in LCDDrecommendations
1. Kidney transplantation for LCDD is an attractive approach for management of end stage renal disease, however, in the absence of long term disease remission, there is ongoing risk of recurrent immunoglobulin deposition and allograft failure.
Further research is needed to define the optimal candidates for this procedure, likely incorporating a sustained period of hematologic remission.
2.
We recommend that for a patient with LCDD to be considered for kidney transplant, prior ASCT or chemotherapy with evidence of a hematologic remission would be required for the best chance for long-term graft survival (Level 4).
| Cryoglobulinemia
Immunoglobulins which precipitate under temperatures less than 37 degrees Centigrade are referred to as cryoglobulins. considered, as many of these patients will achieve remission with anti-neoplastic therapy (Level 4).
For patients who develop cryoglobulinemia post-kidney trans-
plant, treatment of the underlying B-cell clone with agents such as rituximab or alkylators may be of benefit (Level 4).
| C3 glomerulopathy
Recently classified as an MGRS, C3 glomerulopathy (C3G) is a condition characterized by glomerular lesions with C3 complement deposition in the absence of immunoglobulin deposits. 55, 56 In a recently published retrospective analysis of 50 adult patients in France with monoclonal gammopathy and biopsy-proven C3G, some benefit of treatment of the underlying plasma cell dyscrasia, with improvement in renal disease, was noted. 57 In this series, most had severe 
| IMMUNOG LOBULIN LIG HT-CHAIN AMYLOIDOS IS
| Background
The amyloidoses are a heterogeneous group of disorders characterized by deposition of insoluble fibrils as beta-pleated sheets, known as amyloid fibrils. The most common type of amyloidosis is primary systemic immunoglobulin light-chain (AL) amyloidosis, caused by a clonal plasma cell dyscrasia producing amyloidogenic light-chains. Typical sites of organ involvement by amyloidosis include the kidneys in 67%, gastrointestinal tract in 80%, heart in 50%, and nerve involvement in 20% of patients. 58 Left untreated, AL amyloidosis is a devastating condition, often resulting severe morbidity and mortality. The diagnostic criteria for AL are described in Table 2 .
Treatment for newly diagnosed AL amyloidosis consists of combination drug regimens (primarily bortezomib-based) and ASCT.
The goal is to induce remission of the clonal plasma cell dyscrasia that causes amyloid deposition. However, these treatments are not considered curative. 59 Long-term follow-up of these patients who underwent ASCT for AL amyloidosis was published in 2011. The median overall survival was 6.3 years, and 8.3 years for those patients who achieved hematologic complete responses. 60 The critical importance of the hematologic complete response in amyloidosis and all other plasma cell disorders-defined as absence of the abnormal monoclonal protein in blood and urine, and thus, no detectable evidence of disease-lies in its association with long term, durable remissions (ie, a remission characterized by a long period of time without measurable signs of cancer. The duration of time qualified for a remission to be "durable" varies by oncologist, but typically indicates a remission lasting at least 3+ years).
The most frequently used nontransplant treatment for AL amyloidosis is the combination of cyclophosphamide (an alkylator), bortezomib (a proteasome inhibitor), and dexamethasone-known as CyBorD. In an early study, responses were noted in 16 of 17 patients (94%), with a median time to response of only 2 months. 61 Furthermore, it should be noted that the quality of response of AL amyloidosis with bortezomib is outstanding, and recently a study has suggested that the outcome of these patients may be equivalent in patients who have bortezomib-based regimens only or ASCT. 62 Beyond this combination, other new drugs have changed the landscape for AL, such that with relapse of the abnormal protein in the blood, most patients can be successfully treated and achieve repeated remissions. [63] [64] [65] [66] Despite progress in treatments for AL amyloidosis, the disease remains devastating for many, especially those patients with advanced cardiac involvement. 67 For those patients with advanced organ failure, solid organ transplantation-heart or kidney transplantationhas been tested in small case series, often in conjunction with ASCT, though the widespread application of organ transplant has yet to achieve consensus.
| Kidney transplantation in AL amyloidosisbackground
In AL amyloidosis, renal involvement is the most common site of organ involvement, occurring in approximately two-thirds of patients with amyloidosis. 68 Proteinuria is a common manifestation of renal amyloidosis, and many patients will have nephrotic-range proteinuria (up to 28%). 68 Despite effective treatment, many pa- Notably, no allograft failed due to recurrent amyloid deposition; 2 grafts failed from chronic allograft nephropathy, and one related to recurrent pyelonephritis.
| Kidney transplantation in AL amyloidosisrecommendations
1. Limited data in small series of patients suggest that kidney transplantation in AL amyloidosis is feasible, with long-term allograft survival (Level 4). This has been made increasingly possible with improved treatments, including combination therapy with proteasome inhibitors, as well as high-dose therapy.
In select patients with deep and lasting hematologic remissions, kidney transplant should be considered.
2.
Further study is needed to definitively define the optimal patient selection criteria and sequencing of therapies prior to or following kidney transplant to optimize outcomes and reduce risk of recurrent amyloid deposition.
| Cardiac transplantation in AL amyloidosisbackground
Cardiac involvement in AL amyloidosis is both common-seen in at least 50% of patients-and associated with the worst outcomes with respect to overall disease-related mortality. Those patients who present with decompensated congestive heart failure have a median survival of 6 months, with only 6% surviving for 3 years. 68, 73 Unfortunately, due to decline in performance status and severity of heart failure, many of these patients are not eligible for ASCT.
As a strategy to overcome disease injury from cardiac amyloid deposition, cardiac transplantation may allow for receipt of ASCT.
Sequential heart transplantation followed by ASCT has been tested in several centers. Criticism of this approach has focused on 2 critical issues. Transplant hearts remain a limited resource and should be used only in patients in whom long term survival is not expected to be limited. Second, there are concerns that amyloid will recur in the transplanted heart and other organs. Thus, the practice remains controversial and the majority of centers will still not consider patients with amyloid cardiomyopathy for heart transplant.
A first series of patients with AL amyloidosis and significant cardiac involvement who underwent sequential heart transplantation followed by ASCT was published in 2008. 67 In this series, 11 patients underwent sequential heart transplant and ASCT between 1994 and 2005. Treatment-related mortality from ASCT occurred in 2 of the 11 patients (18%). The 1-and 5-year survival from time of heart transplant was 82% and 65%, respectively.
Follow-up of these data were published in 2016. 74 With a total of 23 patients who underwent sequential heart transplant and ASCT-20 of 23 had died since the procedure, with a median OS of 3.5 years for all patients. Nonetheless, patients in whom a durable (deep) hematologic response was achieved had among the best outcomes, with a median OS of 10.8 years in 7 patients with a complete response.
A joint effort from two large tertiary centers, combining heart transplant followed by ASCT at was developed. 76 Of these patients, 6 had received oral melphalan and dexamethasone, and 1 had previously undergone ASCT.
Three patients underwent sequential heart transplant and ASCT.
After a median follow-up of 26 months, 6 were still alive, and 4 patients had a sustained complete response of the underlying disease.
| Cardiac transplantation in AL amyloidosisrecommendations 1.
Further study is warranted to improve outcomes for cardiac transplantation in patients with AL amyloidosis and cardiac involvement.
Although promising results have been described in small series, this approach needs further study in larger clinical trials (Level 3).
2.
The available data lead us to conclude that heart transplant for patients with AL amyloidosis cannot be routinely recommended (Level 3).
| FUTURE D IREC TI ON S
We have attempted to compile and summarize the body of knowledge regarding the management of plasma cell diseases in the organ transplant setting. However, in several arenas, further research is needed. Although the data we summarize suggests no increased risk for MGUS patients undergoing organ transplant, there remain lingering concerns regarding the safety of live donors with an MGUS.
Real concerns exist among the transplant community regarding the suitability of performing organ transplantation for patients with organ failure due to an underlying plasma cell disease; however, with improved novel-agent therapies, and newly-approved monoclonalantibody based therapies, survival and outcomes will continue to improve for many patients with these diseases. It is plausible that in the near future, there will be a tipping point-at which point survival gains due to improved treatments for plasma cell diseases may allow successful organ transplant without putting the allografts at risk for recurrent monoclonal protein induced organ damage.
| CON CLUS ION
Since its inception, solid organ transplantation has emerged as an effective and relatively safe intervention to overcome organ 
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